Early Breast Cancer Adding Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy – The ASCO Post
As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of adjuvant ribo ciclib to a nonsteroidal aromatase inhibitor (NSAI) in patients with hormone receptor–positive, HER2-negative early breast cancer. In the international open-label trial, 5,101 patients with stage II or III disease were randomly assigned between January 2019 and April 2021 to